Milestone Achievement in AI Pharmaceutical Commercialization: First Profitable Company Emerges

The field of AI pharmaceuticals has reached a significant milestone with the emergence of the first profitable company. In the midst of financial reports from various biotech firms, which usually reflect losses for companies without commercialized products, the year 2023 proved to be a pivotal year for AI pharmaceutical companies. This article explores the performance of several publicly listed AI pharmaceutical companies, highlighting the differentiation in their financial outcomes. Notably, one company stands out by achieving profitability for the first time since going public.

The First Tier: Market Value around $2 Billion

Schrodinger: A Game-Changing Profitable Company
Schrodinger, with a market value of $192.6 million, has been recognized as a leader in the AI/drug discovery industry, despite initially denying its classification as an AI company. In 2023, Schrodinger achieved its first-ever profitable year since going public. The company reported a total revenue growth of 20%, with the fourth quarter marking the highest software revenue. Schrodinger's revenue is primarily derived from three sources: software, drug discovery, and other income. All three segments experienced varying degrees of growth, contributing to the company's overall success.

Software revenue, the largest contributor, reached $159.1 million, representing a 17.4% increase. This growth can be attributed to long-term agreements signed with clients, including an increased contract value. Schrodinger's software segment boasts a remarkable gross margin of 81%, with a retention rate of over 98% among customers with annual fees exceeding $500,000. The company's annual contract value (ACV) for 2023 amounted to $154.2 million, a 9.7% increase. Schrodinger's drug discovery revenue grew from $45.4 million in 2022 to $57.5 million in 2023, partly due to a milestone achieved in collaboration with BMS.

Other income, amounting to $220.4 million, primarily resulted from Takeda's acquisition of Nimbus's TYK2 drug for $4 billion, which generated a cash distribution of over $147.2 million for Schrodinger. The company's operating expenses for 2023 totaled $318.1 million, with approximately $182 million allocated to research and development (R&D) for technology platforms and drug discovery projects. Schrodinger aims to focus more resources on patented drug discovery projects in the future, potentially leading to a reduction in collaboration projects over time.

Schrodinger's self-developed pipeline includes SGR-1505 targeting MALT1 and SGR-2921 targeting CDC7, both in Phase I clinical trials. The success of these targets relies on Schrodinger's computational platform, which may need further data disclosure to address selectivity issues. Though one-time income from Nimbus and collaboration with multinational pharmaceutical companies may not be sustainable, Schrodinger's robust cash flow, with approximately $468.8 million in cash and cash equivalents as of December 31, 2023, alleviates concerns about its financial status.

Recursion: A Prominent Player with Notable Transformation

Recursion, a company invested in by NVIDIA, stands out as the highest-valued AI pharmaceutical company, with a market value of $2.386 billion. Despite the hype surrounding NVIDIA's investment, Recursion's performance in 2023 did not shine brightly. The company reported total revenue of $44.6 million, primarily from collaboration agreements, compared to $39.8 million in 2022. However, Recursion recorded a net loss of $328.1 million for the year.

Research and development expenses increased from $155.7 million in 2022 to $241.2 million in 2023. Recursion attributed this increase to expanding and upgrading its platform capabilities, including chemical technologies, machine learning, and transcriptomics. From a strategic standpoint, Recursion appears to be transitioning from an AI biotech company to a tech-bio company.

The emergence of the first profitable AI pharmaceutical company marks a significant milestone in the commercialization of AI-driven drug discovery. Schrodinger's achievement of profitability in 2023 showcases the potential for sustainable business models in this industry. However, challenges lie ahead, such as maintaining profitability amid self-developed pipelines and reducing reliance on one-time income sources. Meanwhile, Recursion, despite its high market value, faces the task of improving its financial performance to match the expectations set by its investors. The AI pharmaceutical landscape continues to evolve, and these companies are at the forefront of revolutionizing drug discovery and development processes.